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Prediction of electro-anatomical 
substrate and arrhythmia 
recurrences using APPLE, DR-
FLASH and MB-LATER scores in 
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undergoing catheter ablation
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Arash Arya1, Daniela Husser1, Andreas Bollmann1, Gregory Y. H. Lip3 & Gerhard Hindricks1
Arrhythmia recurrences after catheter ablation of atrial fibrillation (AF) cause intensive treatment costs. 
Left atrial electro-anatomical remodeling measured as low voltage areas (LVA) during catheter ablation 
indicates advanced disease stage and is associated with poor ablation success. The aim of this study was 
to analyze the prediction of LVA and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER 
scores. APPLE, DR-FLASH scores were calculated at baseline and MB-LATER at 3 months post-ablation 
in AF patients undergoing first catheter ablation. LVA was determined using high-density maps and 
defined as <0.5 mV. Early (ERAF, <3 months) and late (LRAF, 3–12 months) were analyzed during 
follow-up. The study population included 241 patients (age 64 ± 11 years, 59% males, 59% persistent 
AF, 27% LVA, 27% LRAF). LVA were significantly associated with recurrences (OR 2.081, p = 0.026). 
While on univariable analysis, all scores were significantly associated with LVA, on multivariable 
analysis only APPLE (OR 1.789, p < 0.001) and DR-FLASH (OR 2.144, p < 0.001) remained significant 
predictors. However, MB-LATER (OR 1.445, p = 0.034) and ERAF (OR 5.078, p < 0.001) remained 
associated with LRAF on the multivariable analysis. These results were validated in a subgroup of 873 
patients (age 61 ± 10, 63% males, 39% persistent AF, 34% LRAF, 27% LVA) from The Leipzig Heart 
Center AF Ablation Registry. All scores were significantly associated with recurrences. However, ERAF 
was the most powerful predictor for later rhythm outcomes. Summarizing, a clinical score useful for 
prediction for both LVA and rhythm outcomes in AF patients remains a clinical unmet need.
Atrial fibrillation (AF) is the most common cardiac arrhythmia, which is associated with an increased risk of 
dementia, heart failure and thromboembolism, leading to an increased mortality1. Pathophysiological, AF 
results in electrical and later structural remodeling of the atrial myocardium (inflammation, fibrosis, and atrial 
dilatation)2.
Left atrial low voltage areas (LVA), also known as electro-anatomical substrate, represent these atrial remod-
eling processes and are considered to play an important role in AF progression3,4. LVA can be found in 10% of 
patients with paroxysmal AF and in 35% of patients with persistent AF4. However, performing individually tai-
lored substrate modification, a significantly higher arrhythmia-free survival rate compared with a conventional 
approach can be achieved5.
Nevertheless, the prediction of LVA using clinical scores is understudied. Ribo et al. analyzed prediction of 
electro-anatomical substrate using the CHA2DS2-VASc score and demonstrated that high scores were associated 
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with extensive AF substrate and higher recurrence rates after catheter ablation of persistent AF6. The DR-FLASH 
score (based on Diabetes mellitus, Renal dysfunction, persistent AF type, LA diameter >45 mm, Age >65 years, 
female Sex, and Hypertension) was recently introduced to predict LVA and demonstrated a high predictive ability 
(AUC = 0.801, p < 0.001)7. Recently, we introduced the APPLE score (one point for Age >65 years, Persistent AF, 
imPaired eGFR (<60 ml/min/1.73 m2), LA diameter ≥43 mm, EF <50%) for the prediction of AF recurrences 
after catheter ablation in patients undergoing first and re-do intervention8,9. Later, we demonstrated that the 
APPLE score was useful to predict LVA, too10. The MB-LATER score (one point for Male gender, Bundle branch 
block or QRS >120 ms, LA diameter ≥47 mm, AF Type (persistent AF), Early Recurrence <3 months) had been 
developed as the rhythm outcomes score for the prediction of very late arrhythmia recurrences (>12 months) 
after catheter ablation11, but its potential to predict the presence of LVA during catheter ablation is unknown. 
Therefore, the aim of the current study was to compare prediction of LVA and arrhythmia recurrences using the 
APPLE, MB-LATER and DR-FLASH scores in AF patients undergoing first catheter ablation.
Methods
The study population included 241 AF patients from the BioAF cohort initiated at the Heart Center Leipzig 
between 2015 and 2017 as previously described12. All patients underwent first AF radiofrequency catheter abla-
tion and were detailed phenotyped including clinical, imaging, peri-interventional, follow-up data and bio-
data (blood and plasma). Furthermore, a subgroup of 873 patients from The Leipzig Heart Center AF Ablation 
Registry (2007–2011) had been used to validate the results8,13. Exclusion criteria in both cohorts were pregnancy, 
age <18 or >75, valvular AF, cancer, acute or systemic inflammatory diseases. The study was approved by the 
local Ethical Committee (Medical Faculty, Leipzig University) and all patients provided written informed consent 
for participation. All methods were performed in accordance with the relevant guidelines and regulations.
Paroxysmal and persistent AF were defined according to current guidelines1. Paroxysmal AF was defined as 
self-terminating within 7 days after onset. Persistent AF lasted longer than 7 days or required drugs or electrical 
cardioversion for termination. In all patients, transthoracic and transoesophageal echocardiography were per-
formed prior to the ablation. All class I or III antiarrhythmic medications with exception of amiodarone were 
discontinued for at least 5 half-lives before the AF ablation procedure.
Catheter ablation. The electro-anatomical mapping was performed in sinus rhythm. In patients presenting 
with AF, the arrhythmia was terminated by electrical cardioversion and the mapping was further performed in 
sinus rhythm. End-point of the catheter ablation was isolation of the pulmonary veins with proof of both exit 
and entrance block. The electro-anatomical voltage maps of the left atrium excluding the pulmonary veins were 
created using multielectrode spiral catheter with interelectrode distance 2-5-2 or ablation catheter with a 3.5 mm 
electrode tip and contact measurement properties (SmartTouch Thermocool, Biosense Webster, Diamond Bar, 
CA, USA and TactiCath, St Jude Medical (SJM), Saint Paul, MN, USA) as mapping catheter. Electro-anatomical 
mapping was performed using 3-D electro-anatomical mapping systems (Carto, Biosense Webster, Diamond 
Bar, CA, USA or EnSite Precision, SJM). In both mapping systems the cut-off values for defining LVA were iden-
tical: <0.5 mV for low voltage and <0.2 mV for dense scar. Patients underwent high density mapping of left 
atrial voltage using multipolar catheters in combination with auto-annotation algorithms (AutoMap in Precision 
and ConfiDense in Carto 3). Here the number of points was >1000. Points with insufficient catheter-to-tissue 
contact or inside ablation lines were excluded. At the end of the procedure, an attempt to induce AF or left atrial 
macro-reentry tachycardia (LAMRT) was performed using a standardized protocol (burst stimulation with 300, 
250, 200 ms from coronary sinus). According to the underlying LVA and inducible LAMRT additional ablation 
lines were applied.
In the subgroup from The Leipzig Heart Center AF Ablation Registry, LA catheter ablation was performed 
using a well-documented approach13. Briefly, in all patients, circumferential LA ablation lines were placed around 
the antrum of the ipsilateral pulmonary veins (irrigated tip catheter, pre-selected tip temperature of 48 °C, and 
maximum power of 30–50 W). In patients with persistent AF, additional linear lesions were added at the LA roof, 
the basal posterior wall and the LA (mitral) isthmus. At the end of procedure, linear block was confirmed across 
the roof and the mitral isthmus. The isolation of all pulmonary veins with bidirectional block was verified with a 
multipolar circular mapping catheter and was defined as the procedural endpoint.
In both cohorts, after ablation class I and III antiarrhythmic drugs were not routinely initiated. Only patients 
with failed sinus rhythm restoration received previous antiarrhythmic medication during blanking period and 
thereafter dependent on the rhythm in Holter ECG during follow-up. Proton pump inhibitors were added for 4 
weeks. According to the guidelines1, oral anticoagulation was prescribed for 3–6 months after catheter ablation 
depending on risk stratification of stroke using the CHA2DS2-VASc score thereafter.
Follow-up. All patients were followed in the outpatient clinic after catheter ablation. During the follow-up 
period, 4-days (in the BioAF cohort) or 7-days (in The Leipzig Heart Center AF Ablation Registry) Holter ECG 
recordings were performed at 3, 6 and 12 months. Additional ECGs and Holter ECG recordings were obtained 
when patients’ symptoms were suggestive of AF. Early arrhythmia recurrences (ERAF) were defined as any atrial 
arrhythmia lasting longer than 30 seconds and occurring within the first 3 months after procedure. Late arrhyth-
mia recurrences (LRAF) were any atrial arrhythmia lasting >30 s between 3 and 12 months after ablation. If 
electrical or pharmacologic cardioversion and/or repeat procedure were needed after 3 months blanking period, 
this was also considered as an arrhythmia recurrence, i.e. study endpoint.
Statistical analysis. Data are presented as mean and standard deviation (SD) if normally distributed or 
as median [interquartile range] for skewed continuous variables and as proportions for categorical variables. 
Continuous variables were tested for normal distribution using the Kolmogorov-Smirnov test. The differences 
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between continuous values were assessed using an unpaired t-test if normally distributed or Mann–Whitney test 
if skewed continuous variables, and a chi-square test for categorical variables.
Multivariable logistic regression analysis (MV), which included variables with a p-value < 0.1 found on uni-
variable analysis, was performed to identify predictors for LVA and arrhythmia recurrences. We performed mul-
tivariable analyses separately for APPLE, MB-LATER and DR-FLASH scores with adjustment for the variables, 
which were significant in univariable model, but were not included into the scores: Model 1 for the APPLE with 
adjustment for gender, hypertension, diabetes, bundle brunch block, ERAF; Model 2 for the MB-LATER with 
adjustment for hypertension, diabetes, EF, eGFR; Model 3 for the DR-FLASH with adjustment for EF, bundle 
brunch block, ERAF. In patients with available LVA data, LVA was adjusted to each model analyzing prediction 
of arrhythmia recurrences.
ROC (receiver operating characteristic) curves were generated for graphical illustration of APPLE, 
MB-LATER and DR-FLASH scores’ performance in predicting LVA and arrhythmia recurrences, with the area 
under the curve (AUC) being equivalent to the c-index for determining the predictive value for a score.
A p-value < 0.05 was considered statistically significant. All analyses were performed with IBM SPSS Statistics 
for Windows Version 23 (IBM Corp, Armonk, NY, USA).
Results
Study cohorts. The study population consisted of two cohorts: 241 patients from BioAF cohort with avail-
able LVA and rhythm outcomes data and 873 patients from The Leipzig Heart Center AF Ablation Registry used 
for the results validation (215 with available LVA data). The baseline characteristics of both cohorts are presented 
in Tables 1 and 2. Patients in the BioAF cohort were significantly older, had more often persistent AF, worse 
renal function and left ventricular EF, higher BMI, larger LA diameter, hypertension as well as higher APPLE 
and DR-FLASH scores than patients from The Leipzig Heart Center AF Ablation Registry (all p < 0.05, Suppl. 
Table 1). Patients in The Leipzig Heart Center AF Ablation Registry had significantly higher incidence for ERAF 
and LRAF.
Prediction of LVA. LVA were significantly associated with LRAF (OR 2.081, 95% CI 1.092–3.965, p = 0.026). 
On the univariable analysis (Suppl. Table 2), age, female sex, persistent AF, hypertension, diabetes, renal function, 
LA diameter and all scores were significantly associated with LVA. However, on the multivariable analysis, only 
APPLE (OR 1.789, 95% CI 1.316–2.432, p < 0.001) and DR-FLASH (OR 2.144, 95% CI 1.587–2.896, p < 0.001) 
scores remained significant predictors for LVA, while MB-LATER did not reach significance (Suppl. Table 2).
In the ROC curve analyses, all scores showed significant predictive value for LVA (APPLE AUC 0.720, 95% CI 
0.642–0.798, p < 0.001, DR-FLASH AUC 0.770, 95% CI 0.704–0.836, p < 0.001, MB-LATER AUC 0.599, 95% CI 
0.512–0.685, p = 0.026, Fig. 1).
In the validation cohort, all scores were significantly associated with LVA (Suppl. Table 3).
Prediction of arrhythmia recurrences. BioAF cohort. There were 64 patients (27%) with LRAF in the 
BioAF cohort. On univariable analysis, persistent AF, LVA, ERAF and MB-LATER were significantly associated 




p-valueYes (n = 65) No (n = 176) Yes (n = 62) No (n = 179)
Age, years 69 (64–75) 63 (55–71) <0.001 64 (56–69) 65 (58–73) 0.112
Females 55 35 0.005 40 38 0.763
Persistent AF 82 51 <0.001 68 54 0.044
Electro-anatomical substrate — — — 36 21 0.024
eGFR, ml/min/1.73 m2 68 (57–82) 79 (68–93) <0.001 79 (66–89) 76 (63–89) 0.390
BMI, kg/m2 30 (26–33) 29 (26–33) 0.255 31 (27–34) 28 (26–33) 0.025
LA diameter, mm 42 (45–49) 43 (39–48) 0.028 45 (39–48) 44 (40–48) 0.765
EF, % 60 (50–65) 58 (50–65) 0.785 60 (50–65) 59 (50–65) 0.694
CHA2DS2-VASc score 3 (3–4) 2 (1–4) <0.001 3 (1–4) 3 (1–4) 0.996
APPLE score 3 (2–4) 2 (1–2) <0.001 2 (1–3) 2 (1–3) 0.579
DR-FLASH score 5 (4–5) 3 (2–4) <0.001 4 (3–5) 4 (2–5) 0.214
MB-LATER score 2 (1–3) 2 (1–2) 0.053 2 (1–3) 2 (1–3) 0.018
Recurrences 22 (34) 37 (21) 0.024 — — —
Table 1. Baseline characteristics of the BioAF cohort (n = 241). Data presented as mean (IQR) or %. 
Abbreviations: LVA – low voltage areas; AF – atrial fibrillation; BMI – body mass index; eGFR – estimated 
glomerular filtration rate; LA – left atrial; EF – ejection fraction; CHA2DS2-VASc score – congestive heart 
failure, hypertension, age ≥75 y, diabetes, stroke/thromboembolism, vascular disease (s), age 65–74 y, females; 
APPLE score – Age > 65 years, Persistent AF, imPaired eGFR (<60 ml/min/1.73 m2), LA diameter ≥43 mm, EF 
<50%; DR-FLASH score – diabetes mellitus, renal dysfunction, persistent form of AF, LA diameter >45 mm, 
age >65 years, female sex, and hypertension; MB-LATER score – Male gender, Bundle branch block or QRS 
>120 ms, LA diameter ≥47 mm, AF Type (persistent AF), Early Recurrence <3 months.
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MB-LATER (OR 1.445, 95% CI 1.028–2.030, p = 0.034, MV Model 2) and ERAF (OR 5.078 in MV Model 1 and 
OR 5.066 in MV Model 3, both p < 0.001) remained significant predictors for LRAF.
The Leipzig Heart Center AF Ablation Registry. For the validation of predictive value of all scores we performed 
similar analyses in a subgroup of AF patients from The Heart Center Leipzig AF Ablation Registry. In total, 873 
patients (age 61 ± 10, 63% males, 39% persistent AF, 34% LRAF) with available data for all scores’ calculation were 
included into analyses (Table 2).
On the univariable analysis (Suppl. Table 5), age, persistent AF, LA diameter, ERAF and all scores were sig-
nificantly associated with LRAF. On the multivariable analysis, the APPLE (OR 1.550, 95% CI 1.333–1.803, 
p < 0.001), MB-LATER (OR 1.747, 95% CI 1.527–1.998, p < 0.001) and DR-FLASH (OR 1.242, 95% CI 1.118–
1.381, p = 0.001) scores were significant predictors for LRAF. Similarly, as with LRAF prediction in the BioAF 
cohort, ERAF was the most powerful predictor for rhythm outcomes within 3–12 months with almost 4.5-fold 
risk for LRAF (OR 4.436 in MV Model 1 and OR 4.485 in MV Model 3, both p < 0.001).
In the ROC curve analysis, all scores demonstrated a significant predictive ability for LRAF: AUC 0.638, 95% 
CI 0.599–0.676, p < 0.001 for the APPLE score, AUC 0.662, 95% CI 0.624–0.700, p < 0.001 for DR-FLASH, and 
AUC 0.567, 95% CI 0.526–0.607, p = 0.001 for MB-LATER (Fig. 2).
Discussion
To the best of our knowledge, this is the first analysis comparing the prediction for electro-anatomical remod-
elling measured as LVA and rhythm outcomes using APPLE, MB-LATER and DR-FLASH scores. First, the 
APPLE and DR-FLASH scores were significant predictors for LVA. Furthermore, all scores significantly predicted 
arrhythmia recurrences within 3–12 months after catheter ablation in a validation cohort from The Leipzig Heart 
Center AF Ablation Registry. However, the most powerful predictor for LRAF remained ERAF in both cohorts.
Prediction of electro-anatomical substrate. Left atrial structural remodelling plays a major role in AF 
pathogenesis and up to date could be detected invasively using LA voltage mapping during catheter ablation4,14 or 
non-invasively using cardiac MRI15. Voltage-guided substrate modification by targeting LVA in addition to PVI is 
more effective than conventional PVI ablation approaches concerning arrhythmia freedom after the ablation4,5,14. 
Recently, Yagishita et al. showed that a LA voltage cut-off of <1.1 mV for electro-anatomic voltage mapping in 




p-valueYes (n = 300) No (n = 573) Yes (n = 58) No (n = 157)
Age, years 63 (55–70) 61 (54–68) 0.007 69 (61–72) 60 (53–67) <0.001
Females 39 35 0.212 36 19 0.009
Persistent AF 54 31 <0.001 86 57 <0.001
eGFR, ml/min/1.73 m2 95 (76–116) 97 (81–119) 0.100 72 (62–86) 83 (71–94) <0.001
BMI, kg/m2 28 (26–31) 28 (25–31) 0.325 29 (27–31) 28 (27–31) 0.123
LA diameter, mm 44 (40–48) 42 (38–46) <0.001 47 (40–49) 42 (39–47) 0.013
EF, % 60 (54–65) 60 (55–65) 0.040 58 (50–62) 60 (54–64) 0.145
CHA2DS2-VASc score 2 (1–3) 2 (1–3) 0.004 3 (2–4) 1 (1–2) <0.001
APPLE score 2 (1–3) 1 (1–2) <0.001 3 (2–4) 2 (1–2) <0.001
DR-FLASH score 3 (2–4) 3 (2–4) <0.001 5 (4–5) 3 (2–4) <0.001
MB-LATER score 2 (1–3) 2 (1–2) <0.001 3 (2–3) 2 (1–3) 0.035
Recurrences, % — — 43 35 0.277
Table 2. Baseline characteristics of the validation cohort from The Leipzig Heart Center AF Ablation Registry 
(n = 873). *Subgroup from the Leipzig Heart Center AF Ablation Registry with available LVA data (n = 215).
Figure 1. Prediction of LVA using APPLE, DR-FLASH and MB-LATER scores.
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Although LVA is an important risk factor for post-procedural AF4,5, there are no standardized methods to predict 
LVA non-invasively before catheter ablation.
Some studies have analysed the prediction of electro-anatomical substrate using CHADS2 and CHA2DS2-VASc 
scores6, as both scores include the most important risk factors associated with cardiovascular complications in 
AF patients. Furthermore, the DR-FLASH score was developed to predict LVA in patients with AF undergoing 
radiofrequency catheter ablation7. However, clinical variables used by this score are mostly the same as in the 
widely used CHA2DS2-VASc score to predict thromboembolic risk. Nevertheless, it also includes variables as LA 
diameter and AF type, which are associated with AF progression.
The APPLE and MB-LATER scores were both introduced as rhythm outcomes predicting scores. While the 
APPLE score predicted arrhythmia recurrences within one year in patients undergoing first and repeat abla-
tions8,9, the MB-LATER score had been developed for the prediction of arrhythmia recurrences over 12 months 
in patients with arrhythmia-free survival within first year11.
In the current study, we found that APPLE and DR-FLASH significantly predicted LVA before catheter 
ablation. The prediction of electro-anatomical substrate using DR-FLASH score was the best with more than 
2-fold risk for LVA, however, rather expectable, as it is the score developed for the prediction of underlying 
electro-anatomical substrate in AF patients7. Of note, female gender – as a component of DR-FLASH score – was 
recently considered as a risk factor for substrate in AF patients. Indeed, females have a 2-fold risk for LVA17 and an 
almost 3-fold increased risk for AF recurrence following catheter ablation3. Females might probably present with 
clinical AF in a later state of fibro-fatty infiltration, which could explain a higher presence of electro-anatomical 
substrate and worse rhythm outcomes after catheter ablation17. These findings had been also confirmed in our 
current analysis.
In contrast, the APPLE had been developed as the rhythm outcomes prediction score and included such 
relevant components for AF progression as age, AF type and LA diameter8,9. Other components – like EF (an 
indicator for heart failure) and renal dysfunction – are also associated with an electro-anatomical substrate18,19. 
Therefore, the association between the APPLE score and underlying substrate in AF patients is explainable. This 
had been also recently confirmed10.
The MB-LATER score, however, did not reach significance predicting LVA. Although bundle branch block 
(BBB) – as the one of the parameters included in MB-LATER score – could be considered as a predictor for car-
diac fibrotic turn-over in the ventricles mirroring remodelling processes in the atria, on multivariable analyses 
this parameter was not significantly associated with LVA. Interestingly, on multivariable analyses, hypertension 
was associated with almost 4-fold risk for LVA. Hypertension – as one of the most common cardiac diseases – 
leads to the cardiomyocyte hypertrophy and resulting pro-fibrotic changes20,21. Although in multivariable analy-
ses it does not reach significance, importance of hypertension prevention and treatment in AF patients is obvious.
Prediction of arrhythmia recurrences. Arrhythmia recurrences still remain a common issue after cathe-
ter ablation because of the impairment of the quality of life, higher hospitalization rates and consequently inten-
sive treatment costs1. Therefore, on the one hand, there is a considerable clinical interest to predict the risk for 
recurrences already before procedure; on the other one – to shape personalized therapeutic strategies.
There have been multiple studies analysing the impact of different scores on recurrence prediction. First, the 
thromboembolic risk predicting CHADS2 and CHA2DS2-VASc scores demonstrated only modest prediction for 
arrhythmia recurrences21,22. This had led to the development of specific rhythm outcomes prediction scores as 
ALARMEC, BASE-AF2, CAAP-AF and ATLAS23–26. However, the results of these studies are partly difficult to 
interpret because of some non-standardized definitions (especially renal dysfunction and metabolic syndrome) 
and relatively small study populations. The APPLE score had been established for recurrences within 12 months 
after first ablation using 1.145 patients of The Leipzig Heart Center AF Ablation Registry8 as well as after repeat 
catheter ablation in 379 patients9. In both groups, APPLE score showed better ability to predict rhythm outcomes 
than CHADS2 and CHA2DS2-VASc. The MB-LATER score had been introduced to predict very late arrhythmia 
recurrences in patients with arrhythmia-free survival within 3–12 months after ablation11. It was developed using 
small retrospective cohort (n = 133), compared against other clinical scores (ALARMEc, BASE-AF2, APPLE, 
CHADS2, CHA2DS2–VASc, or HATCH), and demonstrated significantly better VLRAF prediction than most 
scores, apart from the APPLE score. Beside its predictive value for LVA, DR-FLASH was also associated with AF 
Figure 2. Prediction of recurrences using APPLE, DR-FLASH and MB-LATER scores.
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recurrences within 12 months after catheter ablation7, however in the initial study only cut-off had been shown 
as predictive.
In the current study, the ERAF demonstrated the best association with LRAF in the BioAF cohort and in 
the retrospective validation subgroup from The Leipzig Heart Center AF Ablation Registry. Of note, among 
all analysed scores, only MB-LATER included early recurrences11. Previously, we demonstrated that patients 
with ERAF had almost 4-fold risk for LRAF occurrence during follow-up13. This had been also confirmed by a 
meta-analysis27. However, ERAF is not available at baseline, therefore, MB-LATER cannot be calculated before 
catheter ablation.
Prediction of electro-anatomical substrate and arrhythmia recurrences. In the current study, 
we found that the APPLE score demonstrated robust predictive value for both LVA and rhythm outcomes. On 
the one hand, it is a simple calculated score with easy obtainable clinical variables; on the other hand, it can be 
calculated already at baseline. Nevertheless, it was not significant for the prediction of arrhythmia recurrences 
in the BioAF cohort. Although both cohorts had been initiated in the same high-volume ablation center and 
performed using radiofrequency ablation approach, the BioAF cohort was initiated almost a decade later. This 
partly explains significant differences in baseline characteristics between both cohorts. While 10 years ago the 
guidelines recommended AF ablation only by failed rhythm and/or frequency control, during the last decade 
we got hard data presenting catheter ablation benefits on morbidity and mortality, what had led to the update 
of currently available AF management guidelines1. Also, during the last years catheter ablation had been more 
frequently recommended in older and comorbid patients. These observations explain why patients in the BioAF 
cohort were significantly older and had more co-morbidities. Also, there were significant differences in ERAF and 
LRAF occurrence between both cohorts. On the one hand, this could be explained by the technical development 
and application of better catheters and mapping systems in the BioAF cohort, on the other hand – by the shorter 
duration of ECG Holter monitoring during follow-up. Both issues might be the reason, why we failed to demon-
strated significant prediction of arrhythmia outcomes using the APPLE score in BioAF cohort.
In general, prediction of arrhythmia recurrences remains complex as not only disease stage and patients’ 
comorbidities play a role, but also operators experience and continuity of the rhythm control. Still, prediction 
of electro-anatomical remodelling and rhythm outcomes remains challenging and obvious clinical unmet need. 
As both are very likely associated with pro-fibrotic changes in atrial myocardium, the prediction of atrial fibrosis 
using non-invasive tools (MRI, blood biomarkers) could influence therapy decisions and help to tailor individu-
alized treatment strategy. Further translational and interdisciplinary studies are needed to elucidate the true role 
of atrial fibrosis and its’ prediction in AF patients.
Study limitations. This study is limited by its observational, retrospective design in a small single-center 
cohort and retrospective results validation. Furthermore, the majority of the patients were not monitored by loop 
recorders; asymptomatic episodes of silent AF could have been missed. Also, there were only patients undergoing 
first radiofrequency AF catheter ablation. The results could differ in patients with repeated procedures or with 
ablation using other sources. Finally, in The Leipzig Heart Center AF Ablation Registry conducted between 2007 
and 2011, the LVA data were available only in 214 patients.
Conclusion
APPLE and DR-FLASH scores were significant predictors for LVA, while the most powerful predictor for the 
rhythm outcomes was ERAF. A clinical score useful for prediction of both LVA and rhythm outcomes after cath-
eter ablation remains a clinical unmet need.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files).
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